Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

Pfizer Eyes Earlier Talzenna Use after Phase 3 Prostate Cancer Win

March 20, 2026

[Fierce Pharma] Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive Phase III trial in metastatic hormone-sensitive prostate cancer. The Phase III Talapro-3 trial met its primary endpoint by showing the combo of Talzenna and Pfizer and Astellas’ prostate cancer drug Xtandi reduced the risk of tumor progression or death compared with Xtandi and placebo.

A Feedback Mechanism from Prostate Cancer Cells to Macrophages, Reinforced by STAT1, Regulates Tumor Progression, and Resistance to Radiotherapy

March 20, 2026

[Cell Death & Disease] Researchers identified a STAT1/lactate/NFκB1/MCP-1 positive feedback mechanism as a driver of prostate cancer progression and resistance to radiotherapy that functioned by interaction to macrophages, which could be potential therapeutic targets for the advanced prostate cancer.

Suppression of PARP1 Enhances PTEN mRNA Therapy in Castration-Resistant Prostate Cancer by Glycolysis Disruption

March 20, 2026

[Molecular Therapy Oncology] Researchers discovered that the loss of phosphatase and tensin homolog (PTEN) function, in combination with elevated poly(ADP-ribose) polymerase expression, significantly shortens the survival of prostate cancer patients.

GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer

March 20, 2026

[GI Innovation (Biospace)] GI Innovation announced that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy in patients with mCRPC in a Phase Ib clinical trial.

Overcoming T Cell Tolerance to Tumor Self-Antigens through Catch-Bond Engineering

March 20, 2026

[Science] Investigators engineered a new class of supercharged T cells that are stronger, longer-lasting, and more precise at killing prostate cancer cells by fine-tuning how they physically interact with tumor cells.

Cereblon (CRBN) Inhibits Prostate Cancer Metastasis by Negatively Regulating 6-Phosphogluconate Dehydrogenase (6PGD)

March 18, 2026

[Oncogene] Researchers uncovered a novel tumor-suppressive role for cereblon (CRBN), a substrate receptor of the CRL4CRBNE3 ubiquitin ligase complex, in modulating prostate cancer metastasis through regulation of 6-phosphogluconate dehydrogenase (6PGD).

PVT1 lincRNA Signals an Androgen-Dependent Transcriptional Activation Program of Oncogenes in Prostate Cancer Cells

March 18, 2026

[International Journal of Cancer] Researchers investigated how PVT1 contributes to the prostate cancer phenotype under androgen stimulation.

Genomic Landscape and Precision Therapy in Prostate Cancer: Current Status and Future Directions

March 18, 2026

[NPJ Precision Oncology] Scientists provide an overview of the current genomic landscape of prostate cancer and discuss recent advances in precision therapy.

LSD1 Promotes Prostate Cancer Cell Proliferation by Upregulating PRAC1 Expression

March 13, 2026

[Scientific Reports] Investigators found that PRAC1 expression is upregulated in prostate cancer cells and that PRAC1 knockdown represses the proliferation of prostate cancer cells.

Exploring DNA Damage Repair Therapeutics in Prostate Cancer Beyond BRCAness

March 13, 2026

[Molecular Cancer Therapeutics] The authors provide an overview of the most frequently observed genomic aberrations affecting DNA repair pathways in prostate cancer and discuss how patient selection needs improvement to identify the population that will eventually benefit from poly (ADP-ribose) polymerase (PARP) enzyme inhibitor treatment beyond BRCA1/2 deficiency.

Inhibition of C-FLIP Alongside TRAIL Treatment Suppresses Prostate Cancer Stem Cell Activity

March 6, 2026

[British Journal of Cancer] Established and primary prostate cancer lines were treated with the cFLIP inhibitor, OH14, in combination with recombinant TRAIL to investigate changes in viability and colony forming potential.

Lnc-ALX1-2:10 Is a Novel Regulator That Enhances Proliferation, Migration, and Invasion in Prostate Cancer Cells

March 6, 2026

[Scientific Reports] Functional studies demonstrated that knockdown of the lnc-ALX1-2 gene cluster suppresses proliferation, migration, and invasion in PC-3 M-1E8 cells, with lnc-ALX1-2:10 showing the most prominent effect.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.